FLSC COMBINED WITH TAT TOXOID AS AN HIV PROPHYLACTIC VACCINE
Robert C Gallo
University Of Maryland Baltimore, 620 W Lexington St, 4th Fl, Baltimore, Md 21201-1508
Grant 3RC2CA148473-01S1 from National Cancer Institute
Abstract: There is increasing evidence that antibodies targeting the CD4 induced (CD4i) epitopes on the HIV envelope spike can facilitate control of viremia and quite possibly protection from transmission after exposure (reviewed in (1, 2)). We have developed a gp120 based immunogen that induces responses that target these highly conserved regions called the Full Length Single Chain (FLSC). In rhesus macaques, a FLSC molecule derived from HIV (BaL) induced immune responses that target these CD4i epitopes and protect against a rectal heterologous challenge in 2 independent studies, one published (3) and another unpublished. Our next challenge is to develop a vaccine which will induce a sustainable immune response. For envelope based vaccines developed thus far, the antibody response is generally not sustained for more than 4 months (reviewed in (4)). Without continued boosting, any protection observed after an initial exposure would wane, making a recent vaccinee susceptible under repeat exposures. To meet this challenge, we propose a co formulation with the Tat toxoid, a biologically inactive but highly immunogenic form of Tat (5-7). Extracellular Tat protein that is released from acutely infected cells causes the suppression of the T cell immune responses including key helper responses that support the induction of antibodies (reviewed in (8, 9). We would propose that inducing an antibody response that would inactivate and clear this extracellular Tat would protect humoral responses to the FLSC. The result would be the sustained production of CD4i antibodies that would protect against multiple challenges. Consequently, our hypothesis is that combining biologically inert but still immunogenic Tat ("Tat Toxoid") with FLSC will prolong and increase protective antibodies induced by FLSC in the face of repeated challenge. We propose to test this hypothesis through the following aims Aim 1. Assess the efficacy provided by the FLSC/Tat toxoid co-administration against rectal challenge with SHIV162p3. Aim 2. Determine if the co-administration with Tat toxoid improves the quantity and sustainability of envelope specific cellular responses and CD4i directed antibody responses before and after challenge. If successful, we will use the data generated by these studies to support further clinical evaluation of the proposed vaccine candidate. Of course, a successful vaccine against HIV would have an enormous global impact on AIDS and AIDS related malignancies. Our goal is to evaluate in a rhesus macaque SHIV model whether a combination of the Full Length Single Chain (FLSC) and Tat toxoid can potentially be preventative vaccine for AIDS and AIDS malignancies
Relevance: Our goal is to evaluate in a rhesus macaque SHIV model whether a combination of the Full Length Single Chain (FLSC) and Tat toxoid can potentially be preventative vaccine for AIDS and AIDS malignancies
Project start date: 2009-09-30
Project end date: 2011-08-31
Budget start date: 30-SEP-2009
Budget end date: 31-AUG-2010
PFA/PA: RFA-OD-09-004
3RC2CA148473-01S1 (2010): $135693
Sponsored Links Excellgen http://Excellgen.com
Grants awarded to Robert C Gallo
Polypeptide Microbicides Targeting CCR5
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute 701 E Pratt Street, Suite 200 Baltimore, Md 212023101
Grant 5P01AI052050-03 from National Institute Of Allergy And Infectious Diseases IRG: ZHD1
Abstract: Unprotected sexual intercourse accounts for the vast majority of new HIV infections worldwide. A disproportionate number of these infections occur in women due to a variety of physiological and behavioral factors. The severity of this problem begs for the development of safe and effective chemical barriers ("topical microbicides") women can use to prevent mucosal HIV infection. Important insights for the development of topical microbicides can be derived from biological determinants for sexual HIV transmission. Three lines of evidence point to the HIV coreceptor, CCR5, is one of the most important. First, CCR5 is well represented on the mucosal epithelial and is the major coreceptor used to enter resident cells. In accordance, the majority of sexually transmitted HIV strains use this coreceptor for infection. Second, the genetic loss of CCR5 is correlated with strong natural resistance to infection. Notably, there is no apparent health consequence associated with the loss of CR5. Third, the natural capacity of certain individuals to produce high levels of HIV-suppressive CCR5. Third, the natural capacity of certain individuals to produce high levels CCR5 ligands correlates with uninfected status despite repeated exposure to HIV. In accordance, primate vaccine studies have correlated increased chemokine production with protection from virus challenge. Based on these findings, our central hypothesis is that effective vaginal microbicides can be based on biological molecules that block the CCR5 entry coreceptor for HIV. To evaluate our hypothesis, we will attempt to block vaginal R5 SHIV infection of rhesus macaques with microbicide formulations consisting of a CCR5 ligand/HIV inhibitor suspended in a carrier vehicle. We will examine two candidate microbicides, each with a distinct set of potentially beneficial features, first for in vitro anti-viral activity and for safety in animal models. Once characterized, they will then be tested for efficacy in the macaque infection model. One formulation will incorporate the -2 isoform of RANTES, a natural and selective CCR5 ligand with potent HIV- suppressive activity, and the second another natural CCR5 ligand, the HIVgp120-CD4 receptor complex formed during HIV attachment. The antiviral component of this formulation will be an immunoadhesin based on our single chain gp120-CD4 chimeric polypeptide, which we recently provided to be a specific inhibitor of R5 HIV infection. Each formulation will use a type of non-phospholipid liposome (Novasomes) that has appeared to be safe for vaginal application in our preliminary studies. This work will be accomplished within the context of three straightforward and synergistic projects. Upon completing this program we expect to have produced at least one candidate vaginal microbicide capable of preventing vaginal infection by a CCR5-tropic SHIV that will have practical utility in humans.
Keywords: AIDS therapy, antiAIDS agent, antiviral agent, drug design /synthesis /production, gene targeting, synthetic peptide
Project start date: 2001-09-28
Project end date: 2005-07-31
5P01AI052050-03 (2003): $1368411
1P01AI052050-01 (2001): $742323
FLSC COMBINED WITH TAT TOXOID AS AN HIV PROPHYLACTIC VACCINE
Robert C Gallo
University Of Maryland Baltimore, 620 W Lexington St, 4th Fl, Baltimore, Md 21201-1508
Grant 1RC2CA148473-01 from National Cancer Institute
Abstract: There is increasing evidence that antibodies targeting the CD4 induced (CD4i) epitopes on the HIV envelope spike can facilitate control of viremia and quite possibly protection from transmission after exposure (reviewed in (1, 2)). We have developed a gp120 based immunogen that induces responses that target these highly conserved regions called the Full Length Single Chain (FLSC). In rhesus macaques, a FLSC molecule derived from HIV (BaL) induced immune responses that target these CD4i epitopes and protect against a rectal heterologous challenge in 2 independent studies, one published (3) and another unpublished. Our next challenge is to develop a vaccine which will induce a sustainable immune response. For envelope based vaccines developed thus far, the antibody response is generally not sustained for more than 4 months (reviewed in (4)). Without continued boosting, any protection observed after an initial exposure would wane, making a recent vaccinee susceptible under repeat exposures. To meet this challenge, we propose a co formulation with the Tat toxoid, a biologically inactive but highly immunogenic form of Tat (5-7). Extracellular Tat protein that is released from acutely infected cells causes the suppression of the T cell immune responses including key helper responses that support the induction of antibodies (reviewed in (8, 9). We would propose that inducing an antibody response that would inactivate and clear this extracellular Tat would protect humoral responses to the FLSC. The result would be the sustained production of CD4i antibodies that would protect against multiple challenges. Consequently, our hypothesis is that combining biologically inert but still immunogenic Tat ("Tat Toxoid") with FLSC will prolong and increase protective antibodies induced by FLSC in the face of repeated challenge. We propose to test this hypothesis through the following aims Aim 1. Assess the efficacy provided by the FLSC/Tat toxoid co-administration against rectal challenge with SHIV162p3. Aim 2. Determine if the co-administration with Tat toxoid improves the quantity and sustainability of envelope specific cellular responses and CD4i directed antibody responses before and after challenge. If successful, we will use the data generated by these studies to support further clinical evaluation of the proposed vaccine candidate. Of course, a successful vaccine against HIV would have an enormous global impact on AIDS and AIDS related malignancies. Our goal is to evaluate in a rhesus macaque SHIV model whether a combination of the Full Length Single Chain (FLSC) and Tat toxoid can potentially be preventative vaccine for AIDS and AIDS malignancies
Keywords: AIDS; AIDS Vaccines; AIDS Virus; AIDS associated cancer; AIDS related cancer; AIDS-Related Malignancy; AIDS-Related Malignant Neoplasm; ATGN; Acquired Immune Deficiency; Acquired Immune Deficiency Syndrome; Acquired Immune Deficiency Syndrome Virus; Acquired Immuno-Deficiency Syndrome; Acquired Immunodeficiency Syndrome; Acquired Immunodeficiency Syndrome Virus; Adjuvant; Amino Acids; Animals; Antibodies; Antibody Formation; Antibody Production; Antibody Response; Antigenic Determinants; Antigens; Antiviral Agents; Antiviral Drugs; Antivirals; Assay; Binding; Binding (Molecular Function); Binding Determinants; Bioassay; Biologic Assays; Biological Assay; Blood Plasma; Blood Sample; Blood specimen; CD4 Positive T Lymphocytes; CD4 T cells; CD4 lymphocyte; CD4+ T cell; CD4+ T-Lymphocyte; CD4-Positive Lymphocytes; Cancers; Cell Count; Cell Number; Cells; Cells, CD4; Clinical Evaluation; Clinical Testing; Collaborations; Data; Drug Formulations; Envelope Glycoprotein gp120, HIV; Epitopes; Exhibits; Face; Fc Receptor; FcR; Formulation; Formulations, Drug; Funding; Goals; HIV; HIV Envelope Protein gp120; HTLV-III; HTLV-III gp120; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Human Virology; Immune response; Immunization; Immunologic Deficiency Syndrome, Acquired; Immunologic Stimulation; Immunological Stimulation; Immunostimulation; Infection Control; Institutes; LAV-HTLV-III; Length; Link; Lymphadenopathy-Associated Virus; Macaca mulatta; Malignant Neoplasms; Malignant Tumor; Mediating; Metabolic Clearance Rate; Modeling; Molecular Interaction; NIH; National Institutes of Health; National Institutes of Health (U.S.); Phase; Plasma; Procedures; Production; Publishing; Reticuloendothelial System, Serum, Plasma; Rhesus; Rhesus Macaque; Rhesus Monkey; SHIV; Sampling; Sensitization, Immunologic; Sensitization, Immunological; Serum, Plasma; T-Cells; T-Lymphocyte; T4 Cells; T4 Lymphocytes; TAT; Testing; Thymus-Dependent Lymphocytes; Toxoids; Trans-Activation of Transcription Protein; Trans-Activator of Transcription of HIV; Transactivating Regulatory Protein; Transmission; United States National Institutes of Health; Vaccines; Viral Burden; Viral Load; Viral Load result; Viremia; Virology, Human; Virus-HIV; WHBLOOD; Whole Blood; aminoacid; antibody biosynthesis; antibody receptor; base; clearance rate; clinical test; env Protein gp120, HIV; experiment; experimental research; experimental study; extracellular; facial; gp120; gp120 ENV Glycoprotein; gp120(HIV); helper T cell; host response; immunogen; immunogenic; immunoglobulin biosynthesis; immunoresponse; improved; malignancy; meetings; neoplasm/cancer; prophylactic; public health relevance; rectal; research clinical testing; research study; response; simian HIV; simian human immunodeficiency virus; tat Protein; thymus derived lymphocyte; transmission process; vaccine candidate; vaccine development; viraemia; viral sepsis; virusemia
Relevance: Our goal is to evaluate in a rhesus macaque SHIV model whether a combination of the Full Length Single Chain (FLSC) and Tat toxoid can potentially be preventative vaccine for AIDS and AIDS malignancies
Project start date: 2009-09-30
Project end date: 2011-08-31
Budget start date: 30-SEP-2009
Budget end date: 31-AUG-2010
PFA/PA: RFA-OD-09-004
1RC2CA148473-01 (2009): $478338
ANNUAL MEETING OF THE INSTITUTE OF HUMAN VIROLOGY
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute
701 E Pratt Street, Suite 200
baltimore, Md 212023101
Grant 5R13AI046078-03 from National Institute Of Allergy And Infectious Diseases IRG: ZAI1
Abstract: The purpose of the Annual Meeting of the Institute of Human Virology is to provide attendees with an overview of and new data concerning current research in the fields of HIV/AIDS and cancer biology. This includes the structure, infection, immune response, therapy and pathogenesis of AIDS/HIV and its complications, as well as an up-to-date understanding of the role of the hepatitis virus in HIV, tumor immunology, oncogenes, and human viral carcinogenesis. Overviews of each of the meeting´s stated topics of study will be provided at the beginning of each session so that attendees will have a framework in which to evaluate the current data presented in each field. The meeting´s duration will be shortened from 7 to 5.5 days (a concern stated by past attendees) and the committee has eliminated concurrent sessions (another concern expressed by past participants). The 1999 Meeting will be held from August 28 through September 2 at the Renaissance Harborplace Hotel in Baltimore. The 2000 Meeting is scheduled for September 10 through September 15 at the same location. Where applicable, the committee invites speakers with conflicting viewpoints to provide multiple perspectives. The General Sessions focus on new data in the various fields. The meeting press policy prohibits the disclosure of data without the presenter´s approval, enabling speakers to discuss their most recent data without fear of losing their ability to publish in peer-reviewed journals. Evenings are set aside for social activities where attendees are able to participate in an informal and free exchange of ideas. This time is typically used to discuss ongoing collaborations and to establish new ones. In addition, the meeting poster session will be held over the conference´s first three days in order to encourage participation in the entire meeting by presenters and will include the opportunity for attendees to interact on a one-on-one basis. Special emphasis is placed by the program committee on identifying women, ethnic/racial minorities, persons with disabilities, and other individuals who have been traditionally underrepresented in science, as speakers, attendees and scholarship recipients
Keywords: AIDS related neoplasm /cancer, human immunodeficiency virus 1, meeting /conference /symposium, oncology AIDS, HIV infection, hepatitis, neoplasm /cancer immunology, oncogene, pathologic process, viral carcinogenesis travel
Project start date: 1999-08-18
Project end date: 2002-07-31
5R13AI046078-03 (2001): $50000
5R13AI046078-02 (2000): $20000
1R13AI046078-01 (1999): $25000
SECOND ANNUAL MEETING OF THE INSTITUTE OF HUMAN VIROLOGY
Robert C Gallo, Professor And Director
University Of Maryland Baltimore 660 W Redwood St, Rm 021 Baltimore, Md 21201
Grant 1R13CA077652-01 from National Cancer Institute IRG: AITC
Abstract: The primary objective of the meeting is to provide participants with a broad overview of current research on HIV, including therapy, animal models, epidemiology, and vaccine design. The meeting will also feature presentations on herpes viruses and HTLV and will aim for cross fertilization of disciplines and ideas. The overview will consist of three and one half days of non-concurrent, state-of-the-art presentations by leaders in all chosen topic areas. Each of the 42 invited speakers will have 35 minutes to review his or her area of research. Ten minutes of discussion will follow each presentation. The general sessions that follow will focus on presentation of new data in each topic area. These sessions will run concurrently, two lectures at a time, for roughly two days. Where possible, the concurrent sessions have been designed to attract different subsets of participants. Each of the roughly 110 invited speakers for the general sessions will have 15 to 30 minutes to make a presentation. Two poster sessions, two tutorial sessions, and a mini symposium on tumor biology are also scheduled. For each tutorial session, 4-6 topics have been chosen for open simultaneous discussion. Each tutorial will run for two hours. The objective of the tutorials is to allow for open discussion of topics that may not be of sufficient general interest to the participants to justify a general session. To encourage free exchange of new ideas and findings, an embargo on the press will be enforced, and the meeting size will be limited to 1200 participants.
Keywords: HTLV /BLV group, Herpesviridae, human immunodeficiency virus, meeting /conference /symposium, disease model, epidemiology, therapy, vaccine development, travel
Project start date: 1997-09-12
Project end date: 1998-09-11
1R13CA077652-01 (1997): $49900
KAPOSI´S SARCOMA: PATHOGENESIS AND NOVEL THERAPY
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute
701 E Pratt Street, Suite 200
baltimore, Md 212023101
Grant 5P01CA078817-04 from National Cancer Institute IRG: NCI
Abstract: Kaposi´s Sarcoma [KS] is a complex neoplasm with significant morbidity especially in men, and prominent in HIV-1 positive homosexual men who experience a high [>30%] occurrence. Since 1988, the Program Director has pioneered etiologic studies of KS, identifying the importance of the HIV-1 induced inflammatory milieu in the proliferation of target spindle cells, and the effects of a pregnancy-associated factor, termed hCG-associated factor (HAF) with potent anti-KS effects. Building upon these initial studies the current Program Project extends these findings by integrating pathogenesis and pre-clinical treatment research to implement a series of carefully integrated strategies. This program grant is dedicated to a comprehensive study of the pathogenesis of KS and the novel mechanisms of HAF. Our overall hypothesis is that KS has its onset in microvascular inflammatory lesions which results from the action of inflammatory cytokines togethers with the HIV-1 Tat protein. The newly discovered human herpes virus 8 (HHV8) harbors human homologue genes which code for factors that also impact this milieu and thus may synergize this proliferative process. Our recent discovery of a characteristic translocation involving chromosome 314 involving the FHIT gene provides a novel molecular strategy for defining the malignant cells of KS and the role of this suppressor gene in carcinogenesis. The general aims of this program are to 1) establish the mechanisms of action of HAF; 2) identify and characterize the active moiety; 3) investigate the role of some HHV8 genes, which are homologs of cellular cytokines and the chemokine receptor, in KS pathogenesis; and, 4) establish the extent to which a specific chromosomal alteration on the short arm of chromosome 3 is diagnostic or prognostic of the stage(s) of KS. This program is composed of four highly interactive projects [Projects 1-4] led by experienced investigators. These projects are supported by close association with an Animal Core [Core B] and a Virus and Cell Biology Core [Core C]. All projects and cores operate under an Administrative Core [Core A]
Keywords: AIDS related neoplasm /cancer, Kaposi`s sarcoma
Project start date: 1998-09-25
Project end date: 2003-07-31
5P01CA078817-04 (2001): $1440823
5P01CA078817-03 (2000): $1386235
5P01CA078817-02 (1999): $1355943
Sponsored Links Excellgen http://Excellgen.com
1P01CA078817-01 (1998): $796815
Institute Of Human Virology Annual Meeting 2003
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute 701 E Pratt Street, Suite 200 Baltimore, Md 212023101
Grant 2R13AI046078-04 from National Institute Of Allergy And Infectious Diseases IRG: AIDS
Abstract: For seven years, the Institute of Human Virology has provided a forum for dedicated scientists in the fields of virology, most specifically HIV/AIDS and cancer biology, to present new data and exchange ideas and views. The Annual Meeting serves as a unique conference with the following aims 1. To disseminate the most current research findings within the selected program topics; 2. To critically assess the impact of new findings on future directions for research; 3. To provide a forum for discussion of current and emerging issues; 4. To identify, support, and build the next generation of AIDS researchers; 5. To increase participation by women, ethnic/racial minorities, and other individuals who have been traditionally underrepresented in science, yet overrepresented in the populations impacted most by the disease, and to increase participation by individuals from the developing world. The Institute of Human Virology (IHV), with the financial support requested in this application, will accomplish these aims a) by attracting world-renown senior scientists as presenters and participants; b) by carefully organizing each dedicated conference session with theoretically divergent perspectives and ethnically diverse participants; c) by enriching the scientific sessions with an open schedule to foster dialog and interaction between and among investigators; d) by reaching out to and promoting the participation of young investigators in poster sessions and scholarship initiatives; and e) by ensuring that conference results are shared with the broader scientific community through publication of all speaker and poster s. The Annual Meeting is strengthened by a strictly enforced press policy, one that protects data presented at the Annual Meeting for future peer-reviewed publication. This policy prohibits the members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. An estimated 900 scientists and clinicians from around the world are expected to participate in this five-day meeting scheduled for September 29-October 3, 2003 at the Baltimore Marriott Waterfront Hotel. The Annual Meeting features a single-track format. Each conference session opens with a senior scientist s overview presentation on the current base of knowledge in the topic of discussion. This overview provides a basis for evaluation of the data presented by a panel of speakers, each sharing the results of their work. The Annual Meeting Program Committee, responsible for the program content, is encouraged to invite speakers with differing perspectives to stimulate open discussion. Posters are displayed throughout the meeting. One evening is set aside for a reception in the poster area to encourage attendance and interaction. Evening social events are provided to encourage participants to meet with current and potential collaborators, and to talk with presenters. The Annual Meeting Scholarship Initiative provides funds to ensure the participation of promising women, ethnic and racial minorities, and other individuals who have been traditionally underrepresented in science, as well as participants from the developing world.
Keywords: AIDS related neoplasm /cancer, human immunodeficiency virus 1, meeting /conference /symposium, virus, AIDS, HIV infection, hepatitis, pathologic process, viral carcinogenesis, virus characteristic, travel
Project start date: 1999-08-18
Project end date: 2004-08-31
2R13AI046078-04 (2003): $38500
INSTITUTE OF HUMAN VIROLOGY ANNUAL MEETING 2005-2010
Robert C Gallo
University Of Maryland Baltimore, 620 W Lexington St, 4th Fl, Baltimore, Md 21201-1508
Grant 5R13AI046078-11 from National Institute Of Allergy And Infectious Diseases
Abstract: For nine years the International Meeting of the Institute of Human Virology (Meeting) has provided a forum for dedicated scientists in the fields of virology, most specifically HIV/AIDS and cancer biology to present new data and exchange ideas and views. The Meeting serves as a unique conference with the following aims 1. To disseminate the most current research findings within the selected program topics; 2. To critically assess the impact of new findings on future directions for research; 3. To provide a forum for discussion of current and emerging issues; 4. To identify, support, and build the next generation AIDS researcher; 5. To increase participation by women ethnic/racial minorities, and other individuals who have been traditionally under represented in science, yet over represented in the populations impacted most by the disease and to increase participation by individuals from the developing world. The Institute of Human Virology (EHV), with the financial support requested in this application, will accomplish these aims a) by attracting world renown senior scientists as presenters and participants; b) by carefully organizing each dedicated conference session with theoretically divergent perspectives and ethnically diverse participants; c) by enriching the scientific sessions with an open schedule to foster dialog and interaction between and among investigators; d) by reaching out to and promoting the participation of young investigators in poster sessions and scholarship initiatives, and e) by ensuring that conference results are shared with the broader scientific community through publication of all speaker and poster s. The Meeting is further strengthened by a strictly enforced press policy, one that protects data presented at the Meeting for future peer-reviewed publication. This policy prohibits the members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. An estimated 650 scientists and clinicians from around the world are expected to participate in this five-day meeting scheduled for August 29 - September 2, 2005 at the Baltimore Waterfront Marriott. To increase participation by FDA and NIH scientists the meetings in 2006-2009 will be alternate between Bethesda and Baltimore in suitable locations. The Meeting for 2005 will offer a combination of single track and dual track lectures. The incorporation of dual track sessions is a result of feedback from our participants who like some of the more specialized sessions that may not be of interest to the entire group but may not be topics at more general meetings they attend including topics like HTLV. This change also allows for more time to be set aside for oral presentations selected from a call for s. Each conference session opens with a senior scientist´s overview presentation on the current base of knowledge in the topic of discussion. This overview provides a basis for evaluation of the data presented by a panel of speakers, each sharing the results of their work. The Annual Meeting Program Committee, responsible for the program content, is encouraged to invite speakers with differing perspectives to stimulate open discussion. Posters are displayed throughout the meeting. One evening is set aside for a reception in the poster area to encourage attendance and interaction. Evening social events are provided to encourage participants to meet with current and potential collaborators, and to talk with presenters. The Annual Meeting Scholarship Initiative provides funds to ensure the participation of promising women, ethnic and racial minorities, and other individuals who have been traditionally underrepresented in science as well as participants from the developing world
Keywords: AIDS; AIDS/HIV; AIDS/HIV problem; Acquired Immune Deficiency; Acquired Immune Deficiency Syndrome; Acquired Immuno-Deficiency Syndrome; Acquired Immunodeficiency Syndrome; Adherence; Adherence (attribute); Area; Authorization; Authorization documentation; Baltimore; Cancer Biology; Chair; Chairman; Chairperson; Chairwoman; Collaborations; Comment; Comment (PT); Comment [Publication Type]; Commentary; Commentary (PT); Communities; Conflict; Conflict (Psychology); Data; Disabled Persons; Disabled Population; Disclosure; Disease; Disorder; Editorial Comment; Editorial Comment (PT); Ensure; Ethnic and Racial Minorities; Evaluation; Event; Fear; Feedback; Financial Support; Floor; Food; Fostering; Fright; Funding; Future; Goals; HIV/AIDS; HIV/AIDS problem; Handicapped; Human Virology; Immunologic Deficiency Syndrome, Acquired; Individual; Information Disclosure; Institutes; International; Investigators; Journals; Lectures; Lectures (PT); Lectures [Publication Type]; Location; Magazine; Meeting s (PT); Meeting s [Publication Type]; Minority Groups; NIH; NIH RFA; National Institutes of Health; National Institutes of Health (U.S.); News; News (PT); News [Publication Type]; Oral; Participant; Peer Review; People with Disabilities; Permission; Persons with Disabilities; Policies; Population; Posters; Posters [Publication Type]; Principal Investigator; Printing; Programs (PT); Programs [Publication Type]; Publications; Published Comment; Publishing; Request for Applications; Research; Research Personnel; Researchers; Retrovirology; Running; SCHED; Schedule; Scholarship; Science; Science of Virology; Scientific Publication; Scientist; Senior Scientist; Time; Travel; United States National Institutes of Health; Viewpoint; Viewpoint (PT); Virology; Visit; Woman; Work; ing; base; conference; data exchange; disabled; disabled people; disease/disorder; experience; interest; knowledge base; lectures; meeting s; meetings; member; news; next generation; posters; programs; skills; social; symposium; virology; web site
Project start date: 1999-08-18
Project end date: 2011-08-31
Budget start date: 1-SEP-2010
Budget end date: 31-AUG-2011
PFA/PA: PAR-03-176
5R13AI046078-11 (2010): $82000
5R13AI046078-10 (2009): $1
7R13AI046078-08 (2007): $1
5R13AI046078-07 (2006): $45999
2R13AI046078-06 (2005): $80500
Institute Of Human Virology Annual Meeting 2004
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute 701 E Pratt Street, Suite 200 Baltimore, Md 212023101
Grant 2R13AI046078-05 from National Institute Of Allergy And Infectious Diseases IRG: AIDS
Abstract: For eight years the International Meeting of the Institute of Human Virology (Meeting) has provided a forum for dedicated scientists in the fields of virology, most specifically HIV/AIDS and cancer biology to present new data and exchange ideas and views. The Meeting serves as a unique conference with the following aims 1. To disseminate the most current research findings within the selected program topics; 2. To critically assess the impact of new findings on future directions for research; 3. To provide a forum for discussion of current and emerging issues; 4. To identify, support, and build the next generation AIDS researcher; 5. To increase participation by women ethnic/racial minorities, and other individuals who have been traditionally under represented in science, yet over represented in the populations impacted most by the disease and to increase participation by individuals from the developing world. The Institute of Human Virology (IHV), with the financial support requested in this application, will accomplish these aims a) by attracting world renown senior scientists as presenters and participants; b) by carefully organizing each dedicated conference session with theoretically divergent perspectives and ethnically diverse participants; c) by enriching the scientific sessions with an open schedule to foster dialog and interaction between and among investigators; d) by reaching out to and promoting the participation of young investigators in poster sessions and scholarship initiatives; and e) by ensuring that conference results are shared with the broader scientific community through publication of all speaker and poster s. The Meeting is further strengthened by a strictly enforced press policy, one that protects data presented at the Meeting for future peer-reviewed publication. This policy prohibits the members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. An estimated 900 scientists and clinicians from around the world are expected to participate in this five-day meeting scheduled for October 31- November 4, 2004 at the Hyatt Regency Baltimore. The Meeting for 2004 will offer a combination of single track and dual track lectures. The incorporation of dual track sessions is a result of feedback from our participants who like some of the more specialized sessions that may not be of interest to the entire group but may be hot topics at more general meetings they attend including topics like HTLV. This change also allows for more time to be set aside for oral presentations selected from a call for s. Each conference session opens with a senior scientist s overview presentation on the current base of knowledge in the topic of discussion. This overview provides a basis for evaluation of the data presented by a panel of speakers, each sharing the results of their work. The Annual Meeting Program Committee, responsible for the program content, is encouraged to invite speakers with differing perspectives to stimulate open discussion. Posters are displayed throughout the meeting. One evening is set aside for a reception in the poster area to encourage attendance and interaction. Evening social events are provided to encourage participants to meet with current and potential collaborators, and to talk with presenters. The Annual Meeting Scholarship Initiative provides funds to ensure the participation of promising women, ethnic and racial minorities, and other individuals who have been traditionally underrepresented in science as well as participants from the developing world.
Keywords: AIDS, AIDS therapy, human immunodeficiency virus 1, medical complication, meeting /conference /symposium, pathologic process, AIDS related neoplasm /cancer, HIV infection, antiAIDS agent, disease reservoir, genetic susceptibility, hepatitis, immune response, virus characteristic, travel
Project start date: 1999-08-18
Project end date: 2005-08-31
2R13AI046078-05 (2004): $96500
1998 MEETING OF THE INSTITUTE OF HUMAN VIROLOGY
Robert C Gallo, Professor And Director
University Of Md Biotechnology Institute
701 E Pratt Street, Suite 200
baltimore, Md 212023101
Grant 1R13AI044673-01 from National Institute Of Allergy And Infectious Diseases IRG: AIDS
Abstract: Adapted ) The objective of the 1998 Meeting of the Institute of Human Virology is to provide domestic and international attendees with a current understanding of research in HIV disease and its complications, including pathogenesis and infection, gene therapy, therapy, animal models, epidemiology, and vaccine design as well as AIDS-associated pathogens and complications, herpes and hepatitis viruses, and cancer. An overview will be provided during two days of non-concurrent state-of-the-art lectures and discussion by scientific leaders in fields of interest. This format gives attendees an up-to-date overview of the field and encourages cross-fertilization and multi-faceted discussions and collaborations. Where applicable, speakers with conflicting viewpoints are chosen to provide multiple perspectives. The General Sessions that will follow the state-of-the-art lectures will focus on new data in the various fields. Presenters in the General Sessions will be able to discuss their most recent data without fear of losing their ability to publish in peer-reviewed journals as the meeting press policy prohibits the disclosure of data without the presenter´s approval. For one half-day, the meeting will move outside for "tutorials," during which 4-6 topics will be chosen for open simultaneous discussion. This forum allows for discussion on specific topics that may not be of enough general interest to justify a General Session. The evening of this day is left open at the tutorial location for the attendees to participate in an informal and free exchange of ideas. This time is typically used by attendees to discuss ongoing collaborations and to establish new ones. In addition, the meeting has two posters sessions (three days total) where attendees interact on a one-on-one basis. The Program Committee, which established the scientific agenda for the meeting, consists of international scientists from academe and government. As part of its effort to attract women, ethnic/racial minorities, individuals from Third World countries, persons with disabilities, and other individuals who have been traditionally underrepresented in science, the Institute gives special scholarship consideration to applicants who meet any of the aforementioned criteria. The Annual Meeting of the Institute of Human Virology has replaced the annual meetings held for more than 15 years by Dr. Robert Gallo in his capacity as Chief of the Laboratory of Tumor and Cell Biology, NCI. This international meeting is unique in its attempt to provide a focused overview of the field of AIDS and related cancers in sessions that, wherever possible, are not simultaneous. Also, to assure that the goal of free exchange of the meeting is not lost, the meeting size will be limited to 1,500 attendees and the press is strictly regulated through a published press policy
Keywords: AIDS, AIDS related neoplasm /cancer, meeting /conference /symposium travel
Project start date: 1998-08-21
Project end date: 1999-08-20
1R13AI044673-01 (1998): $28000